These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36710421)

  • 1. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
    Bowyer AE; Maclean RM; Kitchen S
    Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
    Bowyer AE; Kitchen S; Ezban M
    J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
    Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
    Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.
    Yamaguchi T; Shinozawa K; Nagatoishi S; Mitsuhashi A; Bingo M; Inaba H; Amano K; Tsumoto K; Kinai E
    Thromb Res; 2023 Feb; 222():131-139. PubMed ID: 36657269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
    Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
    Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory issues in gene therapy and emicizumab.
    Bowyer AE; Lowe AE; Tiefenbacher S
    Haemophilia; 2021 Feb; 27 Suppl 3():142-147. PubMed ID: 32469128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
    Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
    Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab.
    Pfrepper C; Klamroth R; Ettingshausen CE; Petros S; Siegemund A; Siegemund T
    Haemophilia; 2024 Mar; 30(2):545-553. PubMed ID: 38343119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
    Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
    Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factor VIII assays in treated hemophilia A patients].
    Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
    Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy.
    Yacoub OA; Duncan EM
    Methods Mol Biol; 2023; 2663():597-610. PubMed ID: 37204739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
    Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
    J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional determination of emicizumab in presence of factor VIII activity.
    Hamedani NS; Donners AAMT; van Luin M; Gasper S; Rühl H; Klein C; Albert T; El Amrani M; Pötzsch B; Oldenburg J; Müller J
    J Thromb Haemost; 2023 Dec; 21(12):3490-3500. PubMed ID: 37741510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement.
    Kershaw G; Dix C; Chen VM; Cai N; Khoo TL
    Pathology; 2022 Oct; 54(6):755-762. PubMed ID: 35577608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
    Peyvandi F; Oldenburg J; Friedman KD
    J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.